2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation

Weinberg, L. R.; Albom, M. S.; Angeles, T. S.; Breslin, H. J.; Gingrich, D. E.; Huang, Z.; Lisko, J. G.; Mason, J. L.; Milkiewicz, K. L.; Thieu, T. V.; Underiner, T.L .; Wells, G. J.; Wells-Knecht, K. J.; Dorsey, B. D.; Bioorg. Med. Chem. Lett., 2011, 21(4), 7325-7330Link to article